Merck KGaA confirms interest in acquiring cancer biotech SpringWorksnews2025-02-10T20:50:58+00:00February 10th, 2025|Endpoints News|
Boehringer Ingelheim touts success in second Phase 3 lung fibrosis trialnews2025-02-10T16:28:02+00:00February 10th, 2025|Endpoints News|
Pliant shares plummet as Phase 2b lung fibrosis study pausednews2025-02-10T12:14:40+00:00February 10th, 2025|Endpoints News|
Doctors complete fourth xenotransplant of gene-edited pig kidneynews2025-02-07T19:25:16+00:00February 7th, 2025|Endpoints News|
Bain buys Mitsubishi Tanabe Pharma in $3.3B bet on Japannews2025-02-07T16:06:41+00:00February 7th, 2025|Endpoints News|
Novo Nordisk takes aim at Roche in hemophilia A, but is way behindnews2025-02-07T12:18:26+00:00February 7th, 2025|Endpoints News|
Roche heads to FDA with Gazyva results in a form of lupusnews2025-02-07T08:45:02+00:00February 7th, 2025|Endpoints News|
Kura’s AML drug succeeds in advanced patients, will take to FDAnews2025-02-05T21:01:58+00:00February 5th, 2025|Endpoints News|
Small personalized vaccine trial sees progress in late-stage kidney cancernews2025-02-05T18:57:30+00:00February 5th, 2025|Endpoints News|
EyePoint shares more mid-stage data for therapy trying to compete with Regeneron’s Eyleanews2025-02-05T16:15:01+00:00February 5th, 2025|Endpoints News|
